The designation was supported by findings from the phase 2 Co-PSMA trial, the phase 1/2 COBRA trial, and real-world evidence.
Commentary|Articles|September 8, 2025
- Vol 53 No 09
- Volume 53
- Issue 09
Medicare proposed rule for 2026: CMS, what are you doing to us?
Author(s)Jonathan Rubenstein, MD, Mark Painter
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
"Based on this proposal, some shifts may significantly impact the practice of urology," write Jonathan Rubenstein, MD, and Mark Painter.
Advertisement
Advertisement
On July 14, 2025, the Centers for Medicare & Medicaid Services (CMS) released the proposed rule for the Calendar Year 2026 Medicare Physician Fee Schedule (MPFS), which outlines proposed payment policies for the care of Medicare beneficiaries. Some significant changes are proposed, continuing the trend of shifting money away from surgical specialists and toward primary care providers.
Related to this article
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.
Earlier genetic testing in men with very low sperm counts may spare unnecessary testing or surgery, according to Ronald Anglade, MD.
Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.
A national survey of US military service members and veterans with NMIBC found that more than half were diagnosed by age 50, while 63% reported treatment access barriers.
VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.
Virtuoso Surgical expects to initiate a focused US launch at leading urology centers in 2027.
Pasritamig is being evaluated with or without JNJ-9401 in the ongoing phase 3 KLK2-comPAS trial.
Advertisement
Advertisement